

Overview of Main Conclusions of the Integrated Science Assessment for Particulate Matter (External Review Draft)

Bay Area Air Quality Management District Advisory Council

Jason Sacks
National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
March 11, 2019



Disclaimer

This presentation is based on information provided in the external review draft Integrated Science Assessment for Particulate Matter. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.



Overview of the Process for Reviewing the PM NAAQS

- **IRP**: Planned approach, schedule
- ISA: Assesses the available scientific information on public health and welfare effects; provides the science foundation for the review
- PA: Transparent

 analysis of the
 adequacy of the current
 standards and, as
 appropriate, potential
 alternatives

2014-2016

Planning
Call for Information, Public Workshop, Integrated Review Plan (IRP)

2018-2020

Assessment
Integrated Science Assessment (ISA), Policy Assessment (PA)

2020

■

Clean Air
Scientific
Advisory
Committee
(CASAC)
review and
public comment

Rulemaking

Agency decision making, interagency review and public comments process

Note: This NAAQS Review Process was originally outlined in Administrator Pruitt's May 9, 2018 "Back to Basics" Memo.

Weight-of-Evidence Approach for Causality Determinations for Health and Welfare Effects

- Provides transparency through structured framework
- Developed and applied in ISAs for all criteria pollutants
- Emphasizes synthesis of evidence across scientific disciplines (e.g., controlled human exposure, epidemiologic, and toxicological studies)
- Five categories based on overall weight-of-evidence:
 - Causal relationship
 - Likely to be a causal relationship
 - Suggestive of, but not sufficient to infer, a causal relationship
 - Inadequate to infer the presence or absence of a causal relationship
 - Not likely to be a causal relationship
- ISA Preamble describes this framework
 - Preamble is now stand-alone document (http://www.epa.gov/isa)
- CASAC extensively reviewed the Agency's causal framework in the process of reviewing ISAs from 2008 – 2015; its use was supported in all ISAs




effect:

Evaluation of the Scientific Evidence

- Organize relevant literature for broad health outcome categories
- Evaluate studies, characterize results, extract relevant data
- Integrate evidence across disciplines for health outcome categories
- Develop causality determinations using established framework
- Evaluate evidence for populations potentially at increased risk

Consideration of evidence spans many scientific disciplines from source to

Atmospheric chemistry
Exposure
Controlled human exposure studies
Epidemiologic studies
Animal toxicologic studies
At-risk populations/lifestages



Informs Hazard Identification step of Risk Assessment Process



relationship

any level of exposure.

populations and lifestages, are mutically consistent in exposure concentrations

Framework for Causality Determinations in the ISA

	Health Effects	Ecological and Other Welfare Effects
Causal relationship	Evidence is sufficient to conclude that there is a causal relationship with relevant pollutant exposures (e.g., two orders of magnitude of recent been shown to result in health effect and other biases could be ruled out (1) controlled human exposure studies in which chance, conformation (2) observational studies that cannot that are supported by other lines of action information). Generally, the describination is based on multiple high-quality studies conducted by multiple research groups.	confounding, and other biases could be ruled out with reasonable confidence. Controlled exposure studies (laboratory unding, and other as tudies) provide the strongest evidence for
Likely to be a causal relationship	Evidence is sufficient to conclude that a causal relationship is likely to exist with relevant pollutant exposures. That is, the pollutant has been shown to result in health effects in studies where results are not explained by chance, confounding, and other biases, but For example: (1) observational studies show an association but copolitant exposures are difficult to address and/or other line. In portant uncertain human exposure, animal, or mode action information are limited or inconsistent, or (2) animal toxicological evidence from multiple studies from different laboratories demonstrate effects, but limited or no human data are available. Generally, the determination is based on multiple high-quality studies.	relevant pollutant exposures. That is, an association has been observed between the pollutant and the outcome in studies in which chance, ality studies there biases are minimized but uncertainties remain. For
Suggestive of, but not sufficient to infer, a causal relationship	effects relevant to humans in animal species, or (2) when the body of evidence is relatively large, evidence from studies of varying quality is generally supportive but not entirely consistent, and there may be coherence across lines of evidence (e.g., animal studies or mode of action information) to support the determination.	
Inadequate to infer a causal relationship	Evidence is inadequate to determine that a causal relationship exists with relevant pollutant exposures. The avail Evidence is of insufficier quality, consistency, or statistical power to permit a conclusion regarding the presence or absence of an effect.	Tevidence is inadequate to determine that a causal relationship exists with available studies are of insufficient quality, the available studies are of insufficient quality, population of statistical power to permit a conclusion regarding the presence tistical power.
Not likely to be a causal	Evidence indicates there is no causal relationship with relevant pollutant exposures. Several adequate studies, covMultiple studies show exposure that human beings are known to multiple studies show	Point indicates there is no causal relationship with relevant pollutant dies examining relationships with relevant to show an effect at any level of exposure.



Contents of the Draft PM ISA

Preface: Legislative Requirements of the PM NAAQS, Purpose and Overview of the ISA, Process for Developing ISA

Executive Summary

Chapter 1. Integrated Synthesis

Chapter 2. Sources, Atmospheric Chemistry, and Ambient Concentrations

Chapter 3. Exposure to Ambient PM

Chapter 4. Dosimetry of PM

Chapters 5 - 11. Respiratory Effects, Cardiovascular Effects, Metabolic Effects, Nervous System Effects, Reproductive and Developmental Effects, Cancer, and Mortality

Chapter 12. Lifestages and Populations Potentially at Increased Risk of a PMrelated Health Effect

Chapter 13. Welfare Effects



Scope

- **Scope:** The ISA is tasked with answering the question "Is there an independent effect of PM on health and welfare at relevant ambient concentrations?"
 - Health Effects
 - Studies will be considered if they include a composite measure of PM (e.g., PM_{2.5} mass, PM_{10-2.5} mass, ultrafine particle (UFP) number)
 - Studies of source-based exposures that contain PM (e.g., diesel exhaust, wood smoke, etc.) if they have a composite measure of PM and examine effects with and without particle trap to assess the particle effect
 - Studies of components of PM if they include a composite measure of PM to relate toxicity of component(s) to current indicator
 - Studies will be considered if PM exposures are relevant to ambient concentrations (< 2 mg/m³; 1 to 2 orders of magnitude above ambient concentrations)



Scope (cont.)

- Welfare Effects
 - Focus is on non-ecological welfare effects
 - Visibility Impairment
 - Climate Effects
 - Materials Effects
 - Ecological effects resulting from the deposition of PM and PM components are being considered as part of the review of the secondary (welfare-based)
 NAAQS for oxides of nitrogen, oxides of sulfur and PM



Executive Summary and Chapter 1

Executive Summary

- High-level overview of main conclusions of the entire ISA
- Briefly captures strengths, limitations, and remaining uncertainties in the evidence base
- Integrated Synthesis (Chapter 1)
 - More detailed synthesis of the scientific evidence compared to the Executive Summary
 - Focus is on those health and welfare effects where it was concluded that a <u>causal</u> or <u>likely to be causal</u> relationship exists
 - Broad characterization of uncertainties and limitations in the evidence for PM_{10-2.5} and UFPs that contributed to a <u>suggestive of, but not sufficient to infer</u> and <u>inadequate</u> causality determination
 - Integrated discussion of policy-relevant issues (e.g., copollutant confounding, concentration-response relationship, sources and components, etc.) spanning the health effects evidence
 - More detailed characterization of the strengths, limitations, and remaining uncertainties in the evidence base



PM Concentrations and Trends (Chapter 2)

• PM_{2.5}

- Steady declining trend 2000 to 2015, with most of the U.S. with annual average < 12 μg/m³
- Annual average decreased from 12 μg/m³ to 8.6 μg/m³ from 2006 to 2014

• PM_{10-2.5}


- Federal Reference Method (FRM) in 2011
- Recent data indicates that the contribution of PM₁₀ to PM₁₀ is higher than previously reported

UFPs


- Highly variable concentration in space and over time due to physical and chemical processing in the atmosphere
- UFP measured using multiple methods, varying in the size ranges examined
- No U.S. monitoring network

PM_{2.5} Components

 Organic carbon has replaced sulfate as the most abundant component of PM_{2.5} in many locations, specifically in the eastern U.S.



2013 - 2015





Exposure to PM (Chapter 3)

Potential Errors and Uncertainty

- Vary depending on the exposure assessment method used
- Evaluations more often occur for methods used in long-term exposure studies

Exposure Error

- Short-term exposure studies: <u>exposure error</u> produces underestimation of health effects
- Long-term exposure studies: exposure error produces <u>underestimation or overestimation</u> of health effects
 - Overestimation of health effects occurs if the exposure model has low spatial resolution and underestimates exposures

Overall

 Necessary to examine individual study details to evaluate potential errors and uncertainty as well as quality of the exposure assessment method used




Figure. Influence of exposure error on health effects associations.



Dosimetry of PM (Chapter 4)

New information in this review:

- Demonstrates that children inhale less through the nose and have lower nasal deposition efficiency than adults resulting in increased exposure of the lungs to inhaled PM
- Shows the translocation of a small fraction of particles (≤ 0.2 μm) out of the respiratory tract from the:
 - Olfactory mucosa to the brain
 - Alveolar region of the lung into blood
- Indicates that PM₁₀ overestimates the size of particles likely to enter the human lung



Oronasal breathing




Draft PM ISA

Health Effects: Causality Determinations

HUMAN HEALTH EFFECTS										
			ISA	Current PM Draft ISA						
			Indicator	PM _{2.5}	PM _{10-2.5}	UFP				
	Do	espiratory	Short-term exposure							
	Ke	spiratory	Long-term exposure							
	Cr	ardiovocaulor	Short-term exposure							
	Cardiovascular		Long-term exposure		*					
	Metabolic		Short-term exposure	*	*	*				
			Long-term exposure	*	*	*				
ıtcome	Nervous System		Short-term exposure	*		*				
alth Ou			Long-term exposure	*	*	*				
He	Reproductive	Male/Female Reproduction and Fertility	Long-term							
	Repro	Pregnancy and Birth Outcomes	exposure							
	Cancer		Long-term exposure	*	*					
	Mortality		Short-term exposure							
	IVIC	or tainty	Long-term exposure		*					
	Causal Likely causal Suggestive Inadequate									
* = new determination or change in causality determination from 2009 PM ISA										



Example: Potential Biological Pathways Figure



Note: The boxes above represent the effects for which there is experimental or epidemiologic evidence, and the dotted arrows indicate a proposed relationship between those effects. Solid arrows denote direct evidence of the relationship as provided, for example, by an inhibitor of the pathway or a genetic knock-out model used in an experimental study. Shading around multiple boxes denotes relationships between groups of upstream and downstream effects. Progression of effects is depicted from left to right and color-coded (gray, exposure; green, initial event; blue, intermediate event; orange, apical event). Here, apical events generally reflect results of epidemiologic studies, which often observe effects at the population level. Epidemiologic evidence may also contribute to upstream boxes. When there are gaps in the evidence, there are complementary gaps in the figure.



Respiratory Effects (Chapter 5)


Recent evidence <u>supports</u> the conclusions of the 2009 PM ISA, and continues to support a <u>likely to be causal</u> relationship between short- and long-term PM_{2.5} exposure and respiratory effects

- Short-term PM_{2.5} Exposure (Likely to be Causal)
 - Epidemiologic evidence: consistent evidence for asthma exacerbation in children and COPD exacerbation in adults, as well as respiratory mortality.
 - <u>Experimental evidence</u>: worsening of allergic airways disease and/or subclinical effects related to COPD, provide biological plausibility for asthma and COPD exacerbations
- Long-term PM_{2.5} Exposure (Likely to be Causal)
 - <u>Epidemiologic evidence</u>: consistent changes in lung function and lung function growth rate, increased asthma incidence, asthma prevalence and wheeze in children; acceleration of lung function decline in adults; and respiratory mortality
 - <u>Experimental evidence</u>: impaired lung development and development of allergic airways disease, biological plausibility for decrements in lung function growth in children and asthma development



Respiratory Effects (Chapter 5)

Example: Short-term PM_{2.5} Exposure and Asthma




Hospital Admissions

Red = recent studies;
Black = U.S. study evaluated in the 2009 PM ISA

Emergency Department Visits

Red = recent studies; Black = U.S. and Canadian studies evaluated in the 2009 PM ISA





Cardiovascular Effects (Chapter 6)


A large body of recent evidence <u>supports and extends</u> the conclusions of the 2009 PM ISA that there is a <u>causal relationship</u> between short-and long-term $PM_{2.5}$ exposure and cardiovascular effects

- Short-term PM_{2.5} Exposure (Causal)
 - Epidemiologic evidence: generally consistent positive associations for hospital admissions and ED visits, particularly for ischemic heart disease (IHD) and heart failure (HF), as well as cardiovascular mortality
 - Experimental evidence: endothelial dysfunction, effects indicating impaired cardiac function, arrhythmia, changes in heart rate variability (HRV), increases in blood pressure (BP), and indicators of systemic inflammation, oxidative stress, and coagulation
- Long-term PM_{2.5} Exposure (Causal)
 - Epidemiologic evidence: consistent positive associations for cardiovascular mortality;
 evidence for coronary heart disease (CHD) and stroke particularly in populations with pre-existing disease; evidence for coronary artery calcification (CAC)
 - Experimental evidence: impaired heart function, increased blood pressure, endothelial dysfunction, and atherosclerotic plaque progression



Cardiovascular Effects (Chapter 6)

Example: Short-term PM_{2.5} Exposure and Cardiovascular-related Mortality



Red = recent studies

Figure 6-7. Percent increase in cause-specific cardiovascular mortality outcomes for a 10 μ g/m³ increase in 24-hour average PM_{2.5} concentrations observed in multicity studies and meta-analyses.



Nervous System Effects (Chapter 8)

- Long-term PM_{2.5} Exposure (Likely to be Causal NEW conclusion)
 - Epidemiologic evidence
 - Consistent evidence for cognitive decline/impairment and decreased brain volume; more limited evidence for Alzheimer's disease and dementia
 - Experimental evidence
 - Consistent evidence for inflammation, oxidative stress, morphologic changes, and neurodegeneration in multiple brain regions of adult animals
 - Limited evidence for early indicators of Alzheimer's disease, impaired learning/memory, altered behavior in adult animals, and morphologic changes during development
- Long-term UFP Exposure (Likely to be Causal NEW conclusion)
 - o Epidemiologic evidence
 - Limited evidence for effects on cognitive development in children
 - Experimental evidence
 - o Consistent evidence for inflammation, oxidative stress, and neurodegeneration in adult animals
 - o Limited evidence of Alzheimer's disease pathology in a susceptible animal model
 - Strong evidence of developmental effects, mainly from one laboratory, for inflammation, morphologic changes including persistent ventriculomegaly, and behavioral effects following pre/postnatal exposure




Cancer (Chapter 10)

- Long-term PM_{2.5} Exposure (Likely to be Causal NEW conclusion)
 - Recent epidemiologic studies greatly expand upon the limited number of studies in the 2009 PM ISA that examined lung cancer incidence and mortality
 - o Primarily positive associations, supported by analyses focusing on never smokers
 - Experimental and epidemiologic studies provide evidence for a relationship between PM_{2.5} exposure and genotoxicity, epigenetic effects, and carcinogenic potential.
 - PM_{2.5} exhibits several characteristics of carcinogens providing biological plausibility for PM_{2.5} exposure contributing to cancer development



Cancer (Chapter 10)




Note: Red = recent studies; Black = studies evaluated in the 2009 PM ISA

Figure 10-3. Summary of associations reported in previous and recent cohort studies that examined long-term $PM_{2.5}$ exposure and lung cancer mortality and incidence.



Mortality – Short-term PM_{2.5} Exposure (Chapter 11) (Causal)

Recent evidence <u>supports and extends</u> the conclusions of the 2009 PM ISA that there is a <u>causal relationship</u> between short-term PM_{2.5} exposure and mortality



Note: Red = recent multi-city studies; Black = multi-city studies evaluated in the 2009 PM ISA

Figure 11-1. Summary of associations between short-term $PM_{2.5}$ exposure and total (nonaccidental) mortality in multicity studies for a 10 μ g/m³ increase in 24-hour average concentrations.




Mortality – Long-term PM_{2.5} Exposure (Chapter 11) (Causal)

Recent evidence <u>supports and extends</u> the conclusions of the 2009 PM ISA that there is a <u>causal relationship</u> between long-term $PM_{2.5}$ exposure and mortality

Figure 11-17.
Associations
between long-term
exposure to PM_{2.5}
and total
(nonaccidental)
mortality in the
American Cancer
Society (ACS)
cohort.

Note: Associations are presented per 5 µg/m³ increase in pollutant concentration.

Red = recent studies; Black = studies evaluated in the 2009 PM ISA



Hazard Ratio (95% Confidence Interval)



Mortality – Long-term PM_{2.5} Exposure (Chapter 11) (Causal)

Figure 11-18.
Associations
between long-term
PM_{2.5} and total
(nonaccidental)
mortality in recent
North American
cohorts.

Note: Associations are presented per 5 µg/m³ increase in pollutant concentration.

Red = recent studies; Black = studies evaluated in the 2009 PM ISA

Reference	Cohort	Notes	Years	Mean (IQR)	1			
†Pope et al. 2014	ACS		1982-2004	12.6	! •			
†Lepeule et al. 2012	Harvard Six Cities		1974-2009		. —			
†Thurston et al. 2015	NIH-AARP		2000-2009		6			
Zeger et al. 2008	MCAPS	Eastern	2000-2005					
Zeger et al. 2008	MCAPS	Western	2000-2005		•			
Zeger et al. 2008	MCAPS	Central	2000-2005		· · ·			
Eftim et al. 2008	ACS-Medicare		2000-2002		i			
†Di et al. 2017	Medicare		2000-2012		i 💆			
†Di et al. 2017	Medicare	exp<12	2000-2012		i			
†Di et al. 2017	Medicare	nearest monitor	2000-2012		i 🔵			
†Kioumourtzoglou et al. 201			2000-2010		ı ——	•		
†Shi et al. 2015	Medicare	mutual adi		8.12 (3.78)	I 			
†Shi et al. 2015	Medicare	exp <10, mutual adj		8.12 (3.78)	—			
†Shi et al. 2015	Medicare	no mutual adj		8.12 (3.78)	I 			
†Shi et al. 2015	Medicare	exp <10, no mutual ad			↓			
†Wang et al. 2017	Medicare	. , . ,	2000-2013		l 🔴	ı		
†Wang et al. 2017	Medicare	exp<12	2000-2013	` '	ı			
Lipfert et al. 2006	Veterans Cohort		1997-2001	· /	۱ ●			
Goss et al. 2004	U.S. Cystic Fibrosis	5	1999-2000	13.7		•		
†Crouse et al. 2012	CanCHEC	Satellite data	1991-2001	8.9				
†Crouse et al. 2012	CanCHEC	Monitor data	1991-2001	11.2	. •			
†Crouse et al. 2015	CanCHEC		1991-2006	8.9	! •			
†Chen et al. 2016	EFFECT		1999-2011	10.7	!			
†Weichenthal et al. 2014	Ag Health		1993-2009	8.84				
†Weichenthal et al. 2014	Ag Health	more precise exp	1993-2009	8.84		_		
†Pinault et al. 2016	CČHS		1998-2011	6.3)		
†Lipsett et al. 2011	CA Teachers		2000-2005	15.6 (8.0)				
†Ostro et al. 2010	CA Teachers	within 30 km	2002-2007	17.5 (6.1)	i	_		
†Ostro et al. 2010	CA Teachers	within 8 km	2002-2007	17 (6.1) ´	i			—
†Ostro et al. 2015	CA Teachers		2001-2007	17.9 (9.6)	P			
†Puett et al. 2009	Nurses Health		1992-2002	13.9 (3.6)	i—			
†Hart et al. 2015	Nurses Health	nearest monitor	2000-2006	12.7	i—			
†Hart et al. 2015	Nurses Health	spatio-temp. model	2000-2006	12	1			
†Puett et al. 2011	Health Prof	full model	1989-2003	17.8 (4.3)				
†Hart et al. 2011	TrIPS		1985-2000	14.1 (4)	ı 			
†Kloog et al. 2013	MA cohort	CVD+Resp	2000-2008	9.9 (1.6)	ı		_	
†Garcia et al. 2015	CA cohort	Kriging	2006	13.06				
†Garcia et al. 2015	CA cohort	IDW	2006	12.94				
†Garcia et al. 2015	CA cohort	closest monitor	2006	12.68				
†Wang et al. 2016	NJ Cohort		2004-2009		I——	_		
Enstrom 2005	CA Cancer Prev		1973-1982	23.4	<u>!</u>			
Enstrom 2005	CA Cancer Prev		1983-2002		•			
Enstrom 2005	CA Cancer Prev		1973-2002	23.4	•			-
					<u> </u>			
				0.8	1	1.2	1.4	1.6

Hazard Ratio (95% Confidence Interval)



Other Causality Determinations (Chapters 5 – 10)

- Limitations and uncertainties in the evidence, along with few or no epidemiologic and experimental studies resulted in conclusions of:
 - -Suggestive of, but not sufficient to infer, a causal relationship, for:
 - PM_{2.5}: repro/dev, nervous system (ST)
 - PM_{10-2.5}: mortality (ST), respiratory (ST), cardiovascular (ST/LT), metabolic (LT), cancer, nervous system (LT)
 - UFP: respiratory (ST), cardiovascular, (ST), nervous system (ST).
 - Inadequate to determine the presence or absence of a causal relationship, for:
 - PM_{10-2.5}: respiratory (LT), metabolic (ST), repro/dev, nervous system (ST)
 - UFP: mortality (ST/LT), respiratory (LT), cardiovascular (LT), metabolic (ST/LT), repro/dev, cancer



States Protection Policy-Relevant Considerations (Chapter 1)

- <u>Copollutant Confounding</u>: Across recent studies examining various health effects and both short- and long-term PM_{2.5} exposures, associations remain <u>relatively unchanged</u> in copollutant models
- Concentration-Response (C-R) Relationship: Across studies evidence continues to support a linear, no-threshold C-R relationship
- PM Components and Sources: Many PM_{2.5} components and sources are associated with many health effects, and the evidence does not indicate that any one source or component is more strongly related with health effects than PM_{2.5} mass




Populations Potentially at Increased Risk of a PM-related Health Effect (Chapter 12)

- The NAAQS are intended to protect both the population as a whole and those potentially at increased risk for health effects in response to exposure to criteria air pollutants
 - Are there specific populations and lifestages at increased risk of a PM-related health effect, <u>compared to a reference population</u>?
- The ISA identified and evaluated evidence for factors that may increase the risk of PM_{2.5}-related health effects in a population or lifestage, classifying the evidence into four categories:
 - Adequate evidence; suggestive evidence; inadequate evidence; evidence of no effect
- Conclusions:
 - Adequate: children and nonwhite populations
 - Suggestive: pre-existing cardiovascular and respiratory disease, overweight/obese, genetic variants glutathione pathways, low SES
 - <u>Inadequate</u>: pre-existing diabetes, older adults, residential location, sex, diet, and physical activity



Draft PM ISA Welfare Effects: Causality Determinations





Welfare Effects (Chapter 13)

Recent evidence <u>supports and extends</u> the conclusions of the 2009 PM ISA that there is a <u>causal relationship</u> between PM and welfare effects

- Visibility Impairment (Causal)
 - Long-term visibility improvements throughout the U.S as PM concentrations have decreased
 - Regional and seasonal patterns in atmospheric visibility parallel PM concentration patterns
 - More evidence supporting the relationship between visibility and PM composition
- Climate Effects (Causal)
 - New evidence provides greater specificity about radiative forcing
 - Increased understanding of additional climate impacts driven by PM radiative effects
 - Improved characterization of key sources of uncertainty particularly with response to PMcloud interactions
- Materials Effects (Causal)
 - New information for glass and metals including modeling of glass soiling
 - Progress in the development of quantitative dose-response relationships and damage functions for materials in addition to stone, including glass and metals
 - Quantitative research on PM impacts on energy yield from photovoltaic systems



PM ISA Team

NCEA Team

Jason Sacks (Assessment Lead) Barbara Buckley (Deputy Lead) Michelle Angrish Renee Beardslee**† Adam Benson*† James Brown Evan Coffman Elizabeth Chan*+ Allen Davis Steve Dutton **Brooke Hemming Erin Hines** Ellen Kirrane **Dennis Kotchmar** Meredith Lassiter Vijay Limaye##† Tom Long

Steve McDow Ihab Mikati*† Jennifer Nichols Molini Patel† Rob Pinder+ Joseph Pinto++ Kristen Rappazzo Jennifer Richmond-**Bryant** Lindsay Stanek# Michael Stewart Chris Weaver

* ORISE ** Postdoctoral Fellow *** NRMRL/OTAQ # NERL ## Region 5 + OAQPS ++ Retired † Separated

NCEA Management (Current)

John Vandenberg, NCEA-RTP Director Steve Dutton, Deputy Director Tara Greaver, Branch Chief (Acting)

NCEA Management (Retired/Previously Acting)

Debra Walsh, Deputy Director (Retired) Reeder Sams, Deputy Directory (Acting) Andrew Hotchkiss, Branch Chief (Acting) Alan Vette, Branch Chief (Acting) Jennifer Richmond-Bryant, Branch Chief (Acting)

Technical Support

Connie Meacham++ Marieka Boyd Ryan Jones Shane Thacker

External Authors

Neil Alexis Matt Campen Sorina Eftim Allison Elder Jay Gandy Katie Holliday Veli Matti Kerminen Igor Koturbash Markku Kulmala Petter Ljungman William Malm

Loretta Mickley

Marianthi-Anna Kioumourtzoglou

James Mulholland Maria Rosa Armistead Russell **Brett Schichtel** Michelle Turner Laura Van Winkle James Wagner **Greg Wellenius** Eric Whitsel Catherine Yeckel Antonella Zanobetti Max Zhang

Tom Luben

April Maxwell*†


Joseph McDonald***



Supplemental Materials



Relationship among Integrated Science Assessments



Notes: Primary (health-based) review of effects on public health = Health

Secondary (welfare-based) review of effects on public welfare = Ecological + Other Welfare

Ecological = effects on soil, water, crops, vegetation, animals, wildlife

Other Welfare = effects on manmade materials, weather, visibility, climate



Example: Evaluation of PM Components Studies Short-term PM_{2.5} and PM_{2.5} Components Exposure and Cardiovascular Effects: Hospital Admissions and Emergency Department (ED) visits – Heat Map


													0 3	
			-/	/2	/	/	/	And Designation of the Party of	/	/		/		/2
		and the S	A de Table	are Ost	913. (216)	Sand Sand	and don't	100	and Dorth	etal Zara	er d. Doras	and Contract	and the same	stal take
		all /	3.	Marie /	old.	Tal.	24	Ada /	1ª /	elal.	24	at C	Tare /	1010
	14	· /38	/ Miles	5 /050	1	150	100	1	15	1	10	13	650	1000
	/	/	40	/	/	/ "	10	/	/	/	/	/	18	/ "
	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD	CVD
PM _{1.6}	0.3	0,0-3	0-1	2	0-1	0-2	8-1	. 0	0	. 0	. 0	0	0	1, 0-6
Carbon														
OC .	0-3		0-1	0,1,2	0	0-2		0,1,2	0		0	0	0	
EC	0-3	0	0-1	9.2	0	0-2		0,1,2	0		0	0	0	1
Major lons					1,000									
SO,2	0-3			0,1,2	0	0-2		0,1,2	0		0	0	0	-
NO ₃	0-3			2	0	0-2		0,1,2	0		0	0	0,1,2	
Metals, Metalloids, Non- Metals														
Ca						0-2			- 1	.0		0	0,1,2	-
V	0-3			0,1,2			0-1			- 0	0	0	0,1,2	
Zn	0-3			0		0-2				.0	0	0	1	-
Si	0.3.	1,2		. 1		0-2		0,1,2			2,3	0	0,1,2	
Na	1					9	9-1	0,1,2	9 7		0	0		
Fe	0/3			0,1,2		0.2						0	0	
К	& sures	4 4		2		0-2					0.00	0	0,1,2	
Cu	0-3			0,1,2		0-2						0	0,1,2	
Ti	g 17			0,1,2								0	0,1,2	
Mn	" "	0,1,2,3		0,1,2								0	0	
Br	B 33			Dec and		1 3	0-1		18 3		0	0		4
Ni Ni	1	3		0,1,2			0-1				0	0	0,1,2	

- Numbers represent lags for which associations observed.
- PM_{2.5} mass or PM_{2.5} components associations categorized by results that are statistically significant positive (dark blue), positive/null (light blue), null/negative (light orange), statistically significant negative (red), or not examined (gray).



Example: Evaluation of PM Components Studies

Short-term PM_{2.5} and PM_{2.5} Components Exposure and Cardiovascular Effects: Hospital Admissions and ED visits – Distribution of Risk Estimates



Bars represent the percent of associations across studies for $PM_{2.5}$ mass or $PM_{2.5}$ components that are statistically significant positive (dark blue), positive (light blue), null/negative (light orange), statistically significant negative (red), or not examined (gray). n = number of studies that provided an estimate for $PM_{2.5}$ mass and individual $PM_{2.5}$ components.



At-Risk Framework Description

Classification	Health Effects
Adequate evidence	There is substantial, consistent evidence within a discipline to conclude that a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. Where applicable, this evidence includes coherence across disciplines. Evidence includes multiple high-quality studies.
Suggestive evidence	The collective evidence suggests that a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage, but the evidence is limited due to some inconsistency within a discipline or, where applicable, a lack of coherence across disciplines.
Inadequate evidence	The collective evidence is inadequate to determine whether a factor results in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. The available studies are of insufficient quantity, quality, consistency, and/or statistical power to permit a conclusion to be drawn.
Evidence of no effect	There is substantial, consistent evidence within a discipline to conclude that a factor does not result in a population or lifestage being at increased risk of air pollutant-related health effect(s) relative to some reference population or lifestage. Where applicable, the evidence includes coherence across disciplines. Evidence includes multiple high-quality studies.



Particulate Matter Symposium



Proposed Symposium on Particulate Matter

- Convened by the Advisory Council as its October 2019 Meeting
- Primary Goal of enabling identification of health focused attainment guidelines beyond those already in effect
- Location to host up to 300 people
- Engage experts who were previously engaged at the Federal level
- Include local health officials and community groups



Deliberation on Questions Related to Particulate Matter



Deliberation on Questions Related to Particulate Matter (PM)

- The Council is invited to deliberate on topics such as:
 - Are current standards sufficiently health protective?
 - What health inequities exist relative to PM?
 - What metrics can be used to address these questions?
 - Concentration?
 - Exposure?
 - Risk (complexities of PM characterization)?
 - Health Outcomes?
 - What are the most important actions that can be taken now?
 And in the future?